Patents Examined by Bruce R. Campell
  • Vaccines containing ribavirin and methods of use thereof
    Patent number: 7261883
    Abstract: The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribavirin and an antigen are described.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: August 28, 2007
    Assignee: Tripep AB
    Inventors: Matti Sällberg, Catharina Hultgren
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 7262286
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: August 28, 2007
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Cell lines for the propagation of mutated herpes viruses
    Patent number: 7262033
    Abstract: A process for propagating a mutant herpes virus having a mutation in its endogenous HSV VP16 gene or a homologue thereof, which process comprises infecting a cell line with the mutant herpes virus and culturing the cell line, wherein the cell line comprises a nucleic acid sequence encoding a functional herpes simplex virus (HSV) VP16 polypeptide, or a homologue thereof, operably linked to a control sequence permitting expression of the polypeptide in said cell line; the nucleic acid sequence being (i) capable of complementing the endogenous gene and (ii) unable to undergo homologous recombination with the endogenous gene. In addition, the present invention provides cell lines which can be used for the growth of mutant herpes viruses which have defects in certain immediate early genes together with mutations in VP16 or homologue thereof.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: August 28, 2007
    Assignee: Biovex Limited
    Inventors: Robert Stuart Coffin, David Seymour Latchman
  • Peptide tag for monitoring and purification of proteins
    Patent number: 7261895
    Abstract: This invention is concerned with a peptide tag having sequence SSTSSDFRDR or GVSSTSSDFRDR derived from transactivator protein E2 of Bovine Papillomavirus type 1, and the fusion polypeptide containing said peptide tag, and the expression vector comprising the oligonucleotide sequence encoding said peptide tag. The invention relates also to the antibodies specific for the peptide tag and the methods for detecting and purifying tagged proteins.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: August 28, 2007
    Assignee: Quattromed Ltd.
    Inventors: Mart Ustav, Reet Kurg, Niilo Kaldalu
  • Polypeptide mediating cell permeability
    Patent number: 7262267
    Abstract: The present invention relates to a cell-permeable polypeptide that can mediate cell permeability to substances, DNA coding for said polypeptide and a method for the production of said polypeptide. The invention also relates to antibodies directed against the polypeptide and the use of said polypeptide in the mediation of cell permeability to substances.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: August 28, 2007
    Assignee: Island Pharmacueticals, Ltd.
    Inventors: Eberhard Hildt, Stephanie Schmidt
  • Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
    Patent number: 7261544
    Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: August 28, 2007
    Assignee: Genzyme Corporation
    Inventors: Guang Qu, John Fraser Wright
  • Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
    Patent number: 7262292
    Abstract: The present invention provides methods and compositions for determining the presence and/or amount of HBV nucleic acids in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting HBV nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the HBV assay.
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: August 28, 2007
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Vijaya Pasupuleti, Hasnah Hamdan, Michael Lewinski
  • Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
    Patent number: 7262270
    Abstract: The present invention provides a fusion protein construct (gp41HA) consisting of the ectodomain of the HIV-1IIIB envelope glycoprotein gp41 fused to a fragment of the influenza virus HA2 hemagglutinin protein. Immunization in-vivo via an intraperitoneal prime followed by intranasal or intragastric boosts with gp41HA induces high concentrations of serum IgG antibodies and fecal IgA antibodies that reacted with gp41 in HIV-1IIIB viral lysate and are cross-reactive with gp41 in HIV-1MN lysate. Followup analyses by indirect immunofluorescence showed that both serum IgG and fecal IgA recognized human peripheral blood mononuclear cells infected with either syncytium-inducing (SI) or non-syncytium-inducing (NSI) North American HIV-1 field isolates, but not uninfected cells.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: August 28, 2007
    Assignee: Children's Medical Center Corporation
    Inventors: Winfried Weissenhorn, David Prashker, legal representative, Nicholas Mantis, Marian R. Neutra, Pamela Kozlowski, Don Wiley, deceased
  • Immunization of dairy cattle with chimeric GapC protein against infection
    Patent number: 7258992
    Abstract: The recombinant production of Gap4, a chimeric GapC plasmin binding protein comprising the entire amino acid sequence of the Streptococcus dysgalactiae GapC protein in addition to unique amino acid sequences from the Streptococcus parauberis and Streptococcus agalactiae GapC proteins, is described. Also described is the use of Gap4 chimeric GapC protein in vaccine compositions to prevent or treat streptococcal infections in general and mastitis in particular.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: August 21, 2007
    Assignee: University of Saskatchewan
    Inventors: Andrew A. Potter, Jose Perez-Casal, Michael Fontaine
  • AAV virions with decreased immunoreactivity and uses therefor
    Patent number: 7259151
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: August 21, 2007
    Assignee: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Diagnostic reagent for hepatitis C virus infection
    Patent number: 7255864
    Abstract: A diagnostic reagent for hepatitis C virus infection obtained by sensitizing a solid phase with HCV antigen and a conjugated antigen prepared by chemical bonding of HCV antigen and a carrier protein, and a method of diagnosing hepatitis C virus infection, which comprises adding the diagnostic reagent for hepatitis C virus infection to a sample, and measuring the degree of agglutination of carrier particles as the solid phase. The diagnostic reagent and the method of diagnosis enable many samples to be measured with higher sensitivity and rapidity.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: August 14, 2007
    Assignee: Sysmex Corporation
    Inventors: Yoichi Takahama, Junichi Shiraishi
  • Compositions for the diagnosis and treatment of epizootic catarrhal enteritis in ferrets
    Patent number: 7255986
    Abstract: The present invention relates to the use of novel nucleotide sequences for the M and N region peptide of the ferret coronavirus and derivative products for the diagnosis and treatment of epizootic catarrhal enteritis (ECE) in ferrets.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: August 14, 2007
    Assignee: The Board of Trustees Operating Michigan State University
    Inventors: Roger K. Maes, Annabel G. Wise, Matti Kiupel
  • Serum biomarkers of Hepatitis B Virus infected liver and methods for detection thereof
    Patent number: 7257365
    Abstract: The invention provides a method for detecting the presence of altered serum proteins in an Hepatitis B Virus (HBV)-infected patient with liver inflammation, comprising: obtaining a sample of serum from the patient; subjecting the sample to protein gel electrophoresis to separate proteins contained therein; staining proteins separated on the electrophoresis gel with silver nitrate solution; scanning the images of stained proteins into an image analysis scanner to obtain gel images; comparing the gel images to control samples of electrophoresis gels prepared from serum of normal patient and serum of HBV-infected patient with liver inflammation to determine whether the sample of serum from the patient contains specific serum proteins. This invention also provides serum protein biomarkers for the diagnosis of patients with HBV infection and liver inflammation.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: August 14, 2007
    Assignee: The University of Hong Kong
    Inventors: Qing-Yu He, Jen-Fu Chiu, George Lau, Yuan Zhou
  • Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
    Patent number: 7256005
    Abstract: Disclosed are methods for screening that may be used to identify an inhibitor of HCV p7 protein. The methods may include incorporating an HCV p7 protein into a membrane to create an HCV p7-containing membrane that has an increased permeability relative to a membrane that does not contain HCV p7 protein. The HCV p7 protein may be contacted with a test compound, and the permeability of this HCV p7-containing membrane then may be compared to an HCV p7-containing membrane in which the HCV p7 protein has not been contacted with the test compound. The inhibitor of HCV p7 protein may be identified by observing a decrease in the permeability of the HCV p7-containing membrane in which the HCV p7 protein has been contacted with the test compound.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: August 14, 2007
    Assignee: The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Nicole Zitzmann, Raymond Allen Dwek Frs
  • Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
    Patent number: 7252818
    Abstract: The present invention relates to the treatment of coronary heart disease by revascularization therapy, and more particularly to the intramyocardial injection of a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 protein or a fragment of a recombinant fibroblast growth factor-1 protein, optionally, with a physiologic glue for inducing local neoangiogenesis in ischemic myocardium. Methods of producing the recombinant fibroblast growth factor 1 protein and fragments are also disclosed.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: August 7, 2007
    Assignee: CardioVascular BioTherapeutics, Inc.
    Inventor: Thomas J. Stegmann
  • Attenuated mutant newcastle disease virus strains for in ovo vaccination, method for preparing and their use
    Patent number: 7252984
    Abstract: The present invention relates to new attenuated mutant New Castle's disease La SotaNewcastle disease virus strains suitable for in ovo vaccination of avian species comprising a mutation in the gene sequences encoding the HN and/or F glycoproteins of said virus. Furthermore, the invention relates to a vaccine composition comprising said attenuated mutant Newcastle's disease La Sota virus strain, and to the use thereof for the preparation of a vaccine for in ovo vaccination of avian species against Newcastle's disease.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: August 7, 2007
    Assignee: Centrum Voor Onderzoek in Diergeneeskunde en Agrochemie
    Inventors: Jan Mast, Guy Meulemans
  • Viruses for the treatment of cellular proliferative disorders
    Patent number: 7252817
    Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering a immunosuppressive agent.
    Type: Grant
    Filed: April 18, 2003
    Date of Patent: August 7, 2007
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Bradley G. Thompson
  • POSH nucleic acids, polypeptides and related methods
    Patent number: 7250250
    Abstract: The application discloses novel polypeptides and nucleic acids involved in a variety of biological processes, including viral reproduction. Related methods and compositions are also described.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: July 31, 2007
    Assignee: Proteologics, Inc.
    Inventors: Iris Alroy, Tsvika Greener, Shmuel Tuvia, Danny Ben-Avraham
  • Mammalian galanin receptors
    Patent number: 7250163
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: July 31, 2007
    Assignee: Schering Corporation
    Inventors: Marvin Bayne, Tanaz Hashemi, Chaogang He, Suke Wang
  • Complex of hepatitis B virus-specific antigenic peptides associated with heat shock proteins and the application thereof
    Patent number: 7247712
    Abstract: The present invention provides a kind of HBV-antigen bound to heat shock proteins (hsps) which comprises core antigen, surface antigen and polymerase antigen. The present invention also provides a complex of HBV antigen bound to heat shock protein gp96 and hsp78, as well as a method for preparing the complex. The complex includes a complex of gp96 and hsp78 non-covalently bound to antigenic polypeptide, as well as a fusion protein of both which results from covalent binding. Such complex can be used to prepare therapeutic vaccine for treating hepatitis B and primary hepatocellular carcinoma.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: July 24, 2007
    Assignee: Institute of Microbiology, Chinese Academy of Sciences
    Inventors: Bo Tian, Songdong Meng, George F. Gao